Kezar Life Sciences (KZR) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KZR shares.
View KZR analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price targets for Kezar Life Sciences' stock. Their KZR share price forecasts range from $13.00 to $20.00. On average, they expect the company's share price to reach $17.33 in the next year. This suggests a possible upside of 506.1% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.

Kezar Life Sciences' stock was trading at $7.04 at the beginning of the year. Since then, KZR stock has decreased by 59.4% and is now trading at $2.86.
View the best growth stocks for 2023 here.

Kezar Life Sciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,940,000 shares, a decrease of 14.8% from the April 30th total of 3,450,000 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is presently 2.9 days.
View Kezar Life Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our KZR earnings forecast.

Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its earnings results on Tuesday, March, 14th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01.

ETFs with the largest weight of Kezar Life Sciences (NASDAQ:KZR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.52%), BlackRock Inc. (6.16%), State Street Corp (4.47%), Sphera Funds Management LTD. (2.61%), Hood River Capital Management LLC (1.98%) and Granahan Investment Management LLC (1.55%). Insiders that own company stock include Equal Talent Investments Ltd, Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends.

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KZR stock can currently be purchased for approximately $2.86.

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $207.09 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.